CONVERT PHARMACEUTICALS
De berekende faillissementskans van CONVERT PHARMACEUTICALS over 12 maanden bedraagt 0,4% (zeer laag). Het bedrijf is actief sinds 2017 en het Belgisch Staatsblad bevat geen insolventie- of waarschuwingssignalen. Er zijn geen verwerkte jaarrekeningcijfers beschikbaar; deze conclusie steunt uitsluitend op register- en Staatsbladgegevens.
| Actief | 9 jaar |
| Bestuur | 1 |
| Vestigingen | 1 |
| Publicaties | 3 |
Statistische inschatting op basis van openbare bronnen, geen kredietadvies of vaststelling. Hoe berekenen we dit?
| Boekjaar | Type | Neerlegging | Referentie |
|---|---|---|---|
| 31-12-2024 | volledig | 26-06-2025 | 2025-00224144 |
| 31-12-2023 | volledig | 06-06-2024 | 2024-00115697 |
| 31-12-2022 | volledig | 08-06-2023 | 2023-00117666 |
| 31-12-2021 | volledig | 12-07-2022 | 2022-20182438 |
| 31-12-2020 | volledig | 22-06-2021 | 2021-23000593 |
| 31-12-2019 | volledig | 29-06-2020 | 2020-22200064 |
| 31-12-2018 | volledig | 02-07-2019 | 2019-26900236 |
| 31-12-2017 | volledig | 09-08-2018 | 2018-44700063 |
-
NOSHAQ Partners SRLRechtspersoonBestuurderStaatsblad-akte 26098965 (31-07-2026)Actief31-07-2026 → heden
| NACE primair | 72109 |
| Rechtsvorm | NV(014) |
| Oprichtingsdatum | 24-02-2017 |
| Status | Actief |
| Postcode | 4000 |
Percelen gekoppeld aan dit bedrijf via zijn adressen in de KBO (zetel, vestigingen, bijkantoren), gekruist met het kadastraal percelenplan. Dit toont waar het bedrijf actief is, geen eigendomsregister.
| Perceel (capakey) | Regio | Oppervlakte | Gebouwen | Hoogte / verd. |
|---|---|---|---|---|
| 62814C0006/00G002 | Wallonië | 6.004 m² | - | - |
Eén tijdlijn van alles wat er met dit bedrijf is gebeurd, publicaties, insolventie- en levensloopgebeurtenissen, administratieve wijzigingen en neergelegde jaarrekeningen.
31-07-2026 General meeting · Officer appointment · Filing representative
- Publication: 31/07/2026 · Convert Pharmaceuticals
- Filing: 14/07/2026 · Convert Pharmaceuticals
- General meeting: 01/06/2026 · Convert Pharmaceuticals
- Officer appointment: role: administrateur, term: six ans, prenant fin à l'issue de l'assemblée générale ordinaire de 2032, start_date: 2026-06-01 · NOSHAQ Partners SRL
- Filing representative: signer et compléter tout document et accomplir toutes les démarches nécessaires auprès des administrations et des tiers, en vue de procéder à l'ensemble des formalités requises pour la mise en oeuvre des résolutions adoptées ci-dessus et leur publication aux Annexes du Moniteur Belge, ainsi que pour procéder aux modifications auprès de la Banque Carrefour des Entreprises et des autres autorités publiques
Technische details
{
"facts": [
{
"date": "2026-07-31",
"type": "publication",
"quote": "Bijlagen bij het Belgisch Staatsblad - 31/07/2026",
"value": "31/07/2026",
"object": null,
"subject": "e1"
},
{
"date": "2026-07-14",
"type": "filing",
"quote": "14 JUIL. 2026",
"value": "14/07/2026",
"object": null,
"subject": "e1"
},
{
"date": "2026-06-01",
"type": "general_meeting",
"quote": "Extrait du proc\u00E8s-verbal de l\u0027assembl\u00E9e g\u00E9n\u00E9rale ordinaire des actionnaires du 1er juin 2026",
"value": "01/06/2026",
"object": null,
"subject": "e1"
},
{
"date": "2026-06-01",
"type": "officer_appointment",
"quote": "L\u0027assembl\u00E9e nomme, (...) NOSHAQ Partners SRL, repr\u00E9sent\u00E8e par Monsieur Hugues Wallemacq, en qualit\u00E9 d\u0027administrateur. Son mandat est conf\u00E9r\u00E9 pour une dur\u00E9e de six ans, prenant fin \u00E0 l\u0027issue de l\u0027assembl\u00E9e g\u00E9n\u00E9rale ordinaire de 2032.",
"value": {
"role": "administrateur",
"term": "six ans, prenant fin \u00E0 l\u0027issue de l\u0027assembl\u00E9e g\u00E9n\u00E9rale ordinaire de 2032",
"start_date": "2026-06-01"
},
"object": "e1",
"subject": "e2",
"_value_raw": {
"role": "administrateur",
"term": "six ans, prenant fin \u00E0 l\u0027issue de l\u0027assembl\u00E9e g\u00E9n\u00E9rale ordinaire de 2032",
"start_date": "01/06/2026"
}
},
{
"type": "filing_representative",
"quote": "L\u0027assembl\u00E9e d\u00E9cide \u00E0 l\u0027unanimit\u00E9 de donner mandat \u00E0 Me Adrien Lanotte, Me Antoine Clerbaux et/ou \u00E0 Me Elise Hamesse, avocats au sein du cabinet Harvest Avocats... aux fins de signer et compl\u00E9ter tout document et accomplir toutes les d\u00E9marches n\u00E9cessaires...",
"value": "signer et compl\u00E9ter tout document et accomplir toutes les d\u00E9marches n\u00E9cessaires aupr\u00E8s des administrations et des tiers, en vue de proc\u00E9der \u00E0 l\u0027ensemble des formalit\u00E9s requises pour la mise en oeuvre des r\u00E9solutions adopt\u00E9es ci-dessus et leur publication aux Annexes du Moniteur Belge, ainsi que pour proc\u00E9der aux modifications aupr\u00E8s de la Banque Carrefour des Entreprises et des autres autorit\u00E9s publiques",
"object": "e1",
"subject": [
"e5",
"e6",
"e7"
]
}
],
"act_meta": {
"outcome": "corrected",
"model_id": 50,
"verified": true,
"extractor": "verified-v1",
"ocr_chars": 2144,
"truncated": false
},
"entities": [
{
"id": "e1",
"kbo": "0671.828.631",
"kind": "company",
"name": "Convert Pharmaceuticals",
"attrs": {
"seat": "Esplanade Simone Veil 1, 4000 Li\u00E8ge",
"legal_form": "Soci\u00E9t\u00E9 anonyme"
}
},
{
"id": "e2",
"kbo": null,
"kind": "company",
"name": "NOSHAQ Partners SRL",
"attrs": {}
},
{
"id": "e3",
"kbo": null,
"kind": "person",
"name": "Hugues Wallemacq",
"attrs": {}
},
{
"id": "e4",
"kbo": null,
"kind": "org",
"name": "Harvest Avocats",
"attrs": {
"address": "1170 Bruxelles, Boulevard du Souverain 100"
}
},
{
"id": "e5",
"kbo": null,
"kind": "person",
"name": "Adrien Lanotte",
"attrs": {}
},
{
"id": "e6",
"kbo": null,
"kind": "person",
"name": "Antoine Clerbaux",
"attrs": {}
},
{
"id": "e7",
"kbo": null,
"kind": "person",
"name": "Elise Hamesse",
"attrs": {}
}
]
}29-08-2025 1 bestuurder benoemd, 1 ontslagnemend
- Brice Van Eeckhout, Directeur
- Paul Tulcinsky, Directeur
Technische details
{
"events": [
{
"kind": "board_snapshot",
"role": "bestuurder",
"person": null,
"reason": null,
"subkind": null,
"via_org": null,
"statutory": null,
"compensated": null,
"effective_date": null,
"evidence_quote": "",
"decharge_status": null,
"mandate_duration": null,
"rep_rotation_new_rep": null,
"rep_rotation_old_rep": null,
"effective_date_qualifier": null
},
{
"kind": "director_out",
"role": "directeur",
"person": {
"rrn": null,
"name": "Paul Tulcinsky",
"address": null,
"birth_date": null,
"profession": null,
"birth_place": null
},
"reason": "death",
"subkind": null,
"via_org": null,
"statutory": null,
"compensated": null,
"effective_date": "2025-02-20",
"evidence_quote": "Les Administrateurs prennent acte de la d\u00E9mission, en sa qualit\u00E9 d\u0027administrateur de la Soci\u00E9t\u00E9, avec effet au 20 f\u00E9vrier 2025, de Monsieur Paul Tulcinsky en raison de son d\u00E9c\u00E8s en date du 20 f\u00E9vrier 2025.",
"decharge_status": null,
"mandate_duration": null,
"rep_rotation_new_rep": null,
"rep_rotation_old_rep": null,
"effective_date_qualifier": "immediate"
},
{
"kind": "director_in",
"role": "directeur",
"person": {
"rrn": null,
"name": "Brice Van Eeckhout",
"address": null,
"birth_date": null,
"profession": null,
"birth_place": null
},
"reason": null,
"subkind": "successor_conditional",
"via_org": null,
"statutory": null,
"compensated": null,
"effective_date": "2025-05-15",
"evidence_quote": "\u00C0 la suite du d\u00E9c\u00E8s de Monsieur Paul Tulcinsky et de la vacance d\u0027un mandat d\u0027administrateur de Soci\u00E9t\u00E9, les Administrateurs d\u00E9cident de coopter, avec effet imm\u00E9diat, Monsieur Brice Van Eeckhout.",
"decharge_status": null,
"mandate_duration": {
"kind": "until_agm_year",
"value": "2026"
},
"rep_rotation_new_rep": null,
"rep_rotation_old_rep": "Paul Tulcinsky",
"effective_date_qualifier": "immediate"
},
{
"kind": "decharge_granted",
"role": "directeur",
"person": {
"rrn": null,
"name": "Brice Van Eeckhout",
"address": null,
"birth_date": null,
"profession": null,
"birth_place": null
},
"reason": null,
"subkind": null,
"via_org": null,
"statutory": null,
"compensated": null,
"effective_date": null,
"evidence_quote": "L\u0027assembl\u00E9e prend acte de la d\u00E9mission, en sa qualit\u00E9 d\u0027administrateur de la Soci\u00E9t\u00E9, avec effet au 20 f\u00E9vrier 2025, de Monsieur Paul Tulcinsky en raison de son d\u00E9c\u00E8s en date du 20 f\u00E9vrier 2025.",
"decharge_status": "granted",
"mandate_duration": null,
"rep_rotation_new_rep": null,
"rep_rotation_old_rep": null,
"effective_date_qualifier": null
}
],
"notary": {
"name": null,
"firm_city": null,
"firm_name": null,
"office_city": null,
"is_associated": false
},
"act_meta": {
"language": "mixed",
"pub_date": "2025-08-29",
"filing_date": "2025-08-05",
"act_kind_objet": "Objet de l\u0027acte:"
},
"decisions": [
{
"body": "conseil_d_administration",
"date": "2024-11-27",
"unanimous": null
},
{
"body": "enig_aandeelhouder_schriftelijk",
"date": "2025-07-01",
"unanimous": null
},
{
"body": "enig_aandeelhouder_schriftelijk",
"date": "2025-05-15",
"unanimous": true
},
{
"body": "algemene_vergadering",
"date": "2025-06-02",
"unanimous": true
}
],
"is_correction": false,
"subject_company": {
"kbo": "0671.828.631",
"name_full": "CONVERT PHARMACEUTICALS",
"legal_form": "SA"
},
"publication_proxy": {
"kind": "org",
"org_kbo": null,
"org_name": "Harvest Avocats",
"person_name": null,
"org_rep_person_name": null,
"person_role_at_subject": null
},
"co_filed_documents": [
"25109962"
],
"corrected_publication_numac": null
}07-07-2025 Kapitaalverhoging van €952.497 tot €2.222.683
- €1.270.186 → €2.222.683
Technische details
{
"events": [
{
"kind": "capital_increase",
"after_eur": 2222683.0,
"delta_eur": 952497.0,
"before_eur": 1270186.0,
"share_emission": {
"agio_eur": null,
"share_form": "no_nominal_value",
"share_class": "A2",
"n_new_shares": 276086,
"with_new_shares": true,
"nominal_value_eur": null,
"issue_price_per_share_eur": null
},
"decrease_purpose": null,
"contribution_type": "apport_nature",
"paid_up_delta_eur": null,
"n_shares_destroyed": null,
"not_yet_called_eur": null,
"merger_new_shares_n": null,
"merger_exchange_ratio": null,
"distribution_amount_eur": null,
"statutory_unavailable_equity_op": null
},
{
"kind": "share_class_creation",
"after_eur": null,
"delta_eur": null,
"before_eur": null,
"share_emission": {
"agio_eur": null,
"share_form": null,
"share_class": null,
"n_new_shares": null,
"with_new_shares": false,
"nominal_value_eur": null,
"issue_price_per_share_eur": null
},
"decrease_purpose": null,
"contribution_type": null,
"paid_up_delta_eur": null,
"n_shares_destroyed": null,
"not_yet_called_eur": null,
"merger_new_shares_n": null,
"merger_exchange_ratio": null,
"distribution_amount_eur": null,
"statutory_unavailable_equity_op": null
},
{
"kind": "share_class_conversion",
"after_eur": null,
"delta_eur": null,
"before_eur": null,
"share_emission": {
"agio_eur": null,
"share_form": null,
"share_class": null,
"n_new_shares": null,
"with_new_shares": false,
"nominal_value_eur": null,
"issue_price_per_share_eur": null
},
"decrease_purpose": null,
"contribution_type": null,
"paid_up_delta_eur": null,
"n_shares_destroyed": null,
"not_yet_called_eur": null,
"merger_new_shares_n": null,
"merger_exchange_ratio": 1.0,
"distribution_amount_eur": null,
"statutory_unavailable_equity_op": null
}
],
"notary": {
"name": "Peter VAN MELKEBEKE",
"firm_city": null,
"firm_name": "Berquin Notaires",
"office_city": "Bruxelles",
"is_associated": true
},
"act_meta": {
"language": "fr",
"pub_date": "2025-07-07",
"filing_date": "2025-07-03",
"act_kind_objet": "Objet de l\u0027acte:"
},
"decision": {
"body": "assembl\u00E9e_generale_extraordinaire",
"act_date": "2025-06-24",
"unanimous": null,
"under_authorized_capital": false,
"underlying_resolution_date": null
},
"bedrijfsrevisor": {
"waived": false,
"firm_kbo": null,
"firm_name": "CDP NICOLET \u0026 C\u00B0 SRL",
"ibr_number": null,
"mission_type": "apport_nature",
"individual_name": "Jean Nicolet"
},
"subject_company": {
"kbo": "0671.828.631",
"name_full": "CONVERT PHARMACEUTICALS",
"legal_form": "Soci\u00E9t\u00E9 anonyme",
"is_foreign_registered": false
},
"publication_proxy": {
"kind": "none",
"org_kbo": null,
"org_name": null,
"person_name": null,
"org_rep_person_name": null,
"person_role_at_subject": null
},
"co_filed_documents": [
"exp\u00E9dition du proc\u00E8s-verbal",
"procuration",
"texte coordonn\u00E9 des statuts",
"rapport de l\u0027organe d\u0027administration",
"rapport du r\u00E9viseur d\u0027entreprises"
],
"shareholders_after": [],
"share_classes_after": [
{
"n_shares": 1943712,
"class_name": "A1",
"capital_share_eur": null,
"voting_rights_per_share": 1.0
},
{
"n_shares": 276086,
"class_name": "A2",
"capital_share_eur": null,
"voting_rights_per_share": 1.0
}
]
}Genereer een gestructureerde, feitelijke nota op basis van alle signalen in dit dossier: risico, financiële gezondheid, eigendomsstructuur, mandaten en sectorvergelijking.
| Officiële naamFR | CONVERT PHARMACEUTICALS |